Total Payments
$48,363
2024 Payments
$5,677
Companies
94
Transactions
2,059
Medicare Patients
14,597
Medicare Billing
$8.4M
Payment Breakdown by Category
Food & Beverage$35,118 (72.6%)
Consulting$10,000 (20.7%)
Education$2,858 (5.9%)
Other$199.40 (0.4%)
Travel$187.15 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $35,118 | 2,001 | 72.6% |
| Consulting Fee | $10,000 | 1 | 20.7% |
| Education | $2,858 | 54 | 5.9% |
| Long term medical supply or device loan | $199.40 | 2 | 0.4% |
| Travel and Lodging | $187.15 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $11,087 | 48 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,813 | 123 | $0 (2024) |
| PFIZER INC. | $2,762 | 245 | $0 (2024) |
| Janssen Biotech, Inc. | $2,657 | 132 | $0 (2024) |
| Genentech USA, Inc. | $1,994 | 132 | $0 (2024) |
| Amgen Inc. | $1,856 | 95 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,670 | 116 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,648 | 96 | $0 (2024) |
| GENZYME CORPORATION | $1,474 | 62 | $0 (2024) |
| Celgene Corporation | $1,417 | 111 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,677 | 258 | PFIZER INC. ($612.54) |
| 2023 | $6,305 | 295 | Janssen Biotech, Inc. ($663.08) |
| 2022 | $5,749 | 302 | Janssen Biotech, Inc. ($559.44) |
| 2021 | $4,558 | 243 | GENZYME CORPORATION ($408.53) |
| 2020 | $3,259 | 190 | AstraZeneca Pharmaceuticals LP ($334.85) |
| 2019 | $5,177 | 283 | AstraZeneca Pharmaceuticals LP ($539.40) |
| 2018 | $14,365 | 272 | Bayer HealthCare Pharmaceuticals Inc. ($10,484) |
| 2017 | $3,273 | 216 | Genentech USA, Inc. ($672.32) |
All Payment Transactions
2,059 individual payment records from CMS Open Payments — Page 1 of 83
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $59.34 | General |
| Category: NONE | ||||||
| 12/16/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: NONE | ||||||
| 12/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.86 | General |
| 12/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/10/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $85.76 | General |
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $83.99 | General |
| 12/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.23 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/02/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: NONE | ||||||
| 11/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Oncology | ||||||
| 11/27/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $21.96 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $19.68 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/21/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Oncology | ||||||
| 11/21/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $5.02 | General |
| Category: Iron Deficiency Anemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 3,099 | 123,737 | $4.0M | $1.6M |
| 2022 | 49 | 3,254 | 143,568 | $5.0M | $2.0M |
| 2021 | 53 | 3,899 | 163,172 | $6.9M | $2.6M |
| 2020 | 57 | 4,345 | 171,568 | $6.2M | $2.2M |
Total Patients
14,597
Total Services
602,045
Medicare Billing
$8.4M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 23,800 | $2.5M | $1.0M | 40.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 292 | 1,003 | $175,555 | $101,460 | 57.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 3,540 | $134,980 | $65,335 | 48.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 60 | 546 | $180,180 | $58,479 | 32.5% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 15 | 145 | $161,043 | $49,057 | 30.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 20 | 7,200 | $161,136 | $43,341 | 26.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 24 | 46,500 | $120,435 | $40,820 | 33.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 80 | 341 | $51,150 | $17,572 | 34.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 132 | 132 | $39,600 | $17,102 | 43.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 369 | 1,876 | $75,040 | $14,247 | 19.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 86 | 90 | $29,700 | $12,793 | 43.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 169 | $18,816 | $11,784 | 62.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 80 | 116 | $21,460 | $11,364 | 53.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 52 | 470 | $35,692 | $11,060 | 31.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 317 | 989 | $39,560 | $10,236 | 25.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 26 | 26,010 | $45,257 | $10,038 | 22.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 29 | 131 | $17,685 | $7,760 | 43.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 113 | $18,645 | $5,980 | 32.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 63 | 512 | $23,055 | $5,858 | 25.4% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 169 | 345 | $10,405 | $5,099 | 49.0% |
| 82746 | Folic acid level, serum | Office | 2023 | 168 | 348 | $10,231 | $5,015 | 49.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 169 | 349 | $9,517 | $4,663 | 49.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 51 | $6,630 | $3,336 | 50.3% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 18 | 126 | $15,732 | $3,288 | 20.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 78 | 108 | $10,800 | $2,996 | 27.7% |
About Dr. Prashant Patel, MD
Dr. Prashant Patel, MD is a Hematology & Oncology healthcare provider based in Stuart, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1336135102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Prashant Patel, MD has received a total of $48,363 in payments from pharmaceutical and medical device companies, with $5,677 received in 2024. These payments were reported across 2,059 transactions from 94 companies. The most common payment nature is "Food and Beverage" ($35,118).
As a Medicare-enrolled provider, Patel has provided services to 14,597 Medicare beneficiaries, totaling 602,045 services with total Medicare billing of $8.4M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Stuart, FL
- Active Since 09/27/2005
- Last Updated 11/02/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336135102
Products in Payments
- Aliqopa (Drug) $10,302
- OPDIVO (Biological) $1,392
- TAGRISSO (Drug) $1,143
- KEYTRUDA (Biological) $1,139
- XTANDI (Drug) $1,038
- LIBTAYO (Biological) $986.77
- DARZALEX (Biological) $914.29
- REBLOZYL (Biological) $706.56
- SARCLISA (Biological) $688.31
- IMBRUVICA (Drug) $688.02
- LYNPARZA (Drug) $578.37
- Avastin (Biological) $568.57
- TECENTRIQ (Biological) $539.82
- IBRANCE (Drug) $520.32
- VENCLEXTA (Drug) $514.09
- Nplate (Biological) $501.04
- Doptelet (Drug) $479.52
- VERZENIO (Drug) $478.72
- JAKAFI (Drug) $472.45
- ERLEADA (Drug) $441.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Stuart
Christine Simone, M.d, M.D
Hematology & Oncology — Payments: $47,158
Hematology & Oncology $47,158
Dr. Joseph My, D.o, D.O
Hematology & Oncology — Payments: $23,464
Hematology & Oncology $23,464
Dr. Ravi Patel, Md, MD
Hematology & Oncology — Payments: $22,473
Hematology & Oncology $22,473
Dr. Cynthia Lopez, Md, MD
Hematology & Oncology — Payments: $1,509
Hematology & Oncology $1,509
Kelley Kozma, Do, DO
Hematology & Oncology — Payments: $439.00
Hematology & Oncology $439.00